Senators Warren and Welch Urge Moderna CEO to Reevaluate Pricing of COVID-19 Vaccine

Trending News 🌥️

Moderna ($NASDAQ:MRNA) Inc. is an American biotechnology company based in Cambridge, Massachusetts that focuses on drug discovery, drug development, and vaccine technologies. Democratic Senators Elizabeth Warren and Peter Welch are urging Moderna CEO Stephane Bancel to reevaluate the pricing of its COVID-19 vaccine. They are concerned that the cost of the vaccine, which Moderna and Pfizer have set at between $110 and $130 per dose, is higher than what the federal government has been paying for it. Warren and Welch are concerned that this pricing could make it difficult for those who cannot afford it to get vaccinated. The Senators also expressed their concerns about Moderna’s ability to scale up production and ensure equitable distribution of the vaccine. They want Moderna to ensure that there is no limit to the number of people who can get vaccinated and that there will be no barriers to access. The Senators believe that Moderna should prioritize providing access to those who are most vulnerable and at risk of contracting the disease.

In response to their letter, Moderna said that it will work with the federal government and other partners to ensure that everyone has access to the vaccine, regardless of their ability to pay. They also stated that they are committed to making sure that the vaccine is available to all the communities and individuals who are in need of it. Moderna’s pricing for its COVID-19 vaccine has been a topic of discussion in recent weeks. While Warren and Welch have raised concerns about the pricing, others have argued that it is necessary to ensure that Moderna can cover its costs and continue to invest in research and development of new vaccines. Ultimately, it is up to Moderna to determine what is a reasonable price for their vaccine and how they can ensure equitable access to it.

Market Price

The senators argued that the high-priced vaccine was preventing many people from accessing it. So far, news coverage of the vaccine has been mostly positive. In response to the senators’ request, Moderna released a statement saying that they are “committed to ensuring broad and equitable access to our COVID-19 vaccine” and that they are working with governments and other partners to ensure that access.

Additionally, they have set up a program to provide free doses of their vaccines to those who cannot afford them. Despite this statement, some are still concerned that the high cost of the vaccine will be a major barrier to those who need it. Furthermore, many healthcare providers are facing financial hardships due to the pandemic and may not be able to afford the vaccine. On Thursday, MODERNA stock opened at $194.4 and closed at $193.2, up by 0.1% from prior closing price of 193.1. This was in contrast to other stocks in the market that were down due to market uncertainty. Despite this slight increase, many investors remain cautious about the stock price due to concerns about pricing and access. Ultimately, it is clear that modern pharmaceutical companies like Moderna play an important role in providing access to life-saving vaccines. It is important that they work with governments, healthcare providers, and other partners to ensure that the prices of these vaccines remain affordable and accessible to all. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Moderna. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Moderna. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Moderna. More…

Key Ratios Snapshot

Some of the financial key ratios for Moderna are shown below. More…

VI Analysis

Moderna Inc. is a high risk investment according to VI Risk Rating, which assesses a company’s financial and business fundamentals. The app has identified four risk warnings on the company’s balance sheet, cash flow statement, non-financial and financial journal. Investors should take into account the company’s long-term potential and risks when considering whether to invest in Moderna. The company’s financial performance is important to consider, as it will affect the company’s ability to generate returns for shareholders. This includes assessing the company’s profitability, liquidity, and asset quality. Investors should also consider the company’s business strategy and competitive landscape. It is important to consider the company’s management team, including its board of directors and executive leadership. Investors should also evaluate the company’s corporate governance practices, which will affect its ability to create long-term value for shareholders. Additionally, investors should determine whether the company has any legal or regulatory issues that could affect its performance. In short, Moderna presents a high risk investment opportunity and investors should evaluate the company’s fundamentals carefully before investing. It is important to analyze the company’s financials, business strategy, and corporate governance practices in order to make a well-informed decision. More…

VI Peers

Moderna Inc is a biotechnology company that develops and manufactures drugs, vaccines, and diagnostics. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts. Moderna Inc’s main competitors are BioNTech SE, Pfizer Inc, and Novavax Inc.

– BioNTech SE ($NASDAQ:BNTX)

BioNTech SE is a German biotechnology company founded in 2008. The company has a market cap of 33.72B as of 2022 and a Return on Equity of 71.82%. BioNTech focuses on the development of innovative therapies for the treatment of cancer and other diseases. The company’s most advanced product is a vaccine for the treatment of human papillomavirus (HPV). BioNTech is also developing a number of other vaccines and therapies for the treatment of cancer, infectious diseases, and autoimmune disorders.

– Pfizer Inc ($NYSE:PFE)

Pfizer Inc is a global pharmaceutical company with a market cap of 247.45B as of 2022. The company’s return on equity is 24.63%. Pfizer’s products include prescription and over-the-counter medicines, vaccines, and animal health products. The company operates in over 150 countries and serves patients and customers across the globe.

– Novavax Inc ($NASDAQ:NVAX)

Novavax is a clinical-stage biotechnology company focused on the discovery, development and commercialization of vaccines to prevent serious infectious diseases. Novavax’s market cap as of 2022 is 1.46B and its ROE is 487.21%. The company’s lead product candidates are NVX-CoV2373, which is in Phase III clinical trials for the prevention of COVID-19, and ResVax, which is in Phase III clinical trials for the prevention of respiratory syncytial virus (RSV) disease.

Summary

Investors are closely monitoring Moderna, a biotechnology company developing a mRNA-based vaccine for COVID-19, as the company is poised to become the first to receive emergency use authorization from the US Food and Drug Administration. Moderna’s stock price has surged in response to news of its successful clinical trials, and many analysts are bullish on the company’s potential. However, some have urged Moderna’s CEO to reconsider pricing for the vaccine to ensure it is accessible to those who need it most.